Taken together, these findings indicate that NPC CSC marker CD44 is an ERK-dependent downstream serglycin effector, and that the capacity of self-renewal in NPC CSCs is possibly maintained by ECM serglycin-activating ERK signaling pathway. The gene discussed is CD44; the disease is nasopharyngeal carcinoma.